Clinical Trial Update: Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates how dosing and frequency of Bacillus Calmette-Guérin (BCG) administration affect T-lymphocyte profiles in individuals with Type 1 d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• BCG (Bacillus Calmette-Guérin) (Bacillus Calmette-Guérin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED